Evidence map›Paper›PMID 40445203›Full record

ArticleMicrobiology spectrum2025

Antibacterial activity of eravacycline against

Yuanzhi Gong, Yuhao Liu, Yunlou Zhu, Shikui Mu, Hanlu Gao, Xin Jing, Yingying Du, Sheng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Eravacycline: From broad-spectrum coverage to novel clinical applications.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuanzhi Gong *Department of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yuhao Liu *Department of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yunlou ZhuDepartment of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Shikui MuDepartment of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Hanlu GaoDepartment of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Xin JingDepartment of Critical Care Medicine, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Yingying DuIntensive Care Medical Centre, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-3945-8778
Sheng WangIntensive Care Medical Centre, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0003-3439-4696

Funding

Cinical Research Project of the Shanghai Municipal Health Commission No. 202340254Shanghai Hospital Development Center Foundation No. SHDC22023234
6 · The paper itself

Abstract

Eravacycline, a novel tetracycline antibiotic, may be an effective treatment option for IMPORTANCE: Carbapenem-resistant

Indexed as

Anti-Bacterial AgentsKlebsiella pneumoniaeTetracyclinesBacterial ProteinsDrug Resistance, Multiple, BacterialDrug SynergismHumansKlebsiella InfectionsMicrobial Sensitivity TestsPolymyxin BAnti-Bacterial AgentsBacterial ProteinseravacyclinePolymyxin BTetracyclinesantibiotic combination treatmenteravacyclineKlebsiella pneumoniaepolymyxin B

Identifiers

PMID40445203
PMCPMC12210908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.